Literature DB >> 3168386

Half-strength TAC topical anesthetic. For selected dermal lacerations.

W A Bonadio1, V Wagner.   

Abstract

A prospective evaluation of 75 consecutive children with lacerations of the face, lip, and scalp who received TAC (tetracaine, epinephrine [adrenalin], cocaine) topical anesthetic for the repair of their wound was performed. The TAC preparation contained one-half the conventional concentration of cocaine (5.9%) and tetracaine (0.25%) previously used in other studies that have evaluated its anesthetic efficacy. A maximal dosage of 3 ml of TAC (containing 175 mg cocaine and 7.5 mg tetracaine) was applied to each laceration. The diluted TAC preparation provided complete anesthesia for approximately 95% of the more than 400 sutures placed. No adverse reactions were noted in any patient who received TAC, and in no instance did a complication of wound healing occur. The original formulation of TAC was arbitrarily composed, and the maximum concentration per dosage of the potentially toxic component medications of TAC that can be "safely" applied to dermal lacerations in children remains to be defined. Utilization of this diluted preparation will diminish the risk of potential systemic toxicity from the absorbed component medications of TAC without compromising anesthetic efficacy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3168386     DOI: 10.1177/000992288802701006

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  3 in total

Review 1.  Topical anaesthetics for pain control during repair of dermal laceration.

Authors:  Baraa O Tayeb; Anthony Eidelman; Cristy L Eidelman; Ewan D McNicol; Daniel B Carr
Journal:  Cochrane Database Syst Rev       Date:  2017-02-22

2.  Topical adrenaline and cocaine gel for anaesthetising children's lacerations. An audit of acceptability and safety.

Authors:  D W G Kennedy; Z Shaikh; M J Fardy; R J Evans; StJ V Crean
Journal:  Emerg Med J       Date:  2004-03       Impact factor: 2.740

3.  Percutaneous dermal drug delivery for local pain control.

Authors:  Sujatha Tadicherla; Brian Berman
Journal:  Ther Clin Risk Manag       Date:  2006-03       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.